Key Substitutions in the Spike Protein of SARS-CoV-2 Variants Can Predict Resistance to Monoclonal Antibodies, but Other Substitutions Can Modify the Effects

Mutations in the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants can compromise the effectiveness of therapeutic antibodies. Most clinical-stage therapeutic antibodies target the spike receptor binding domain (RBD), but variants often have multiple mutations in...

Descripción completa

Detalles Bibliográficos
Autores principales: Lusvarghi, Sabrina, Wang, Wei, Herrup, Rachel, Neerukonda, Sabari Nath, Vassell, Russell, Bentley, Lisa, Eakin, Ann E., Erlandson, Karl J., Weiss, Carol D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Vaccines and Antiviral Agents
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8754225/
https://www.ncbi.nlm.nih.gov/pubmed/34668774
http://dx.doi.org/10.1128/JVI.01110-21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8754225/
https://www.ncbi.nlm.nih.gov/pubmed/34668774
http://dx.doi.org/10.1128/JVI.01110-21

Ejemplares similares